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Abstract
Background: Metastasis is the number one cause of cancer deaths. Expression microarrays have been widely used
to study metastasis in various types of cancer. We hypothesize that a meta-analysis of publicly available gene
expression datasets in various tumor types can identify a signature of metastasis that is common to multiple tumor
types. This common signature of metastasis may help us to understand the shared steps in the metastatic process
and identify useful biomarkers that could predict metastatic risk.
Methods: We identified 18 publicly available gene expression datasets in the Oncomine database comparing
distant metastases to primary tumors in various solid tumors which met our eligibility criteria. We performed a
meta-analysis using a modified permutation counting method in order to obtain a common gene signature of
metastasis. We then validated this signature in independent datasets using gene set expression comparison
analysis with the LS-statistic.
Results: A common metastatic signature of 79 genes was identified in the metastatic lesions compared with
primaries with a False Discovery Proportion of less than 0.1. Interestingly, all the genes in the signature, except one,
were significantly down-regulated, suggesting that overcoming metastatic suppression may be a key feature
common to all metastatic tumors. Pathway analysis of the significant genes showed that the genes were involved
in known metastasis-associated pathways, such as integrin signaling, calcium signaling, and VEGF signaling. To
validate the signature, we used an additional six expression datasets that were not used in the discovery study.
Our results showed that the signature was significantly enriched in four validation sets with p-values less than 0.05.
Conclusions: We have modified a previously published meta-analysis method and identified a common metastatic
signature by comparing primary tumors versus metastases in various tumor types. This approach, as well as the
gene signature identified, provides important insights to the common metastatic process and a foundation for
future discoveries that could have broad application, such as drug discovery, metastasis prediction, and
mechanistic studies.
Background
Metastasis, the process involving the spread of cancer,
accounts for greater than 90% of cancer deaths [1].
However, therapies to treat those patients with advanced
disease are largely ineffective. It is, therefore, imperative
that we improve the understanding of the metastatic
process and detect patients at risk for developing
metastatic disease early, in order to intervene earlier and
improve their survival [2].
Metastasis is a complex process involving many steps.
For example, in order to form a clinically significant
metastasis through the hematogenous route, a cancer
cell must detach from the cells surrounding it (a process
known as the epithelial to mesenchymal transition or
EMT), invade the surrounding extracellular matrix,
enter and survive in the peripheral circulation, exit the
circulation in an organ suitable for metastasis, and then
survive and proliferate in the new environment [3]. A
cancer cell has to accumulate many genetic and
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any medium, provided the original work is properly cited.epigenetic alterations in order to acquire all of the above
functions necessary to become metastatic. Many of these
alterations may manifest themselves though altered gene
expression. The interruption of any one or more of
these steps could potentially inhibit the development of
clinically significant metastasis [3]. More than 32 genes
that are important in suppressing the development of
metastasis in one or more human cancers have been
identified to date [4].
Rationale
While different cancer types do not necessarily have the
same genetic program for metastasis, Ramaswamy et al
described a single molecular signature of metastasis,
identified in the comparison of metastatic and non-
metastatic adenocarcinomas, that could predict out-
comes in various cancers, including breast, prostate, and
even medulloblastoma, a non-epithelial pediatric brain
tumor [5]. It was therefore our hypothesis that there are
common genes and pathways of metastasis shared by
multiple cancer types, and that by expanding the above
analysis to incorporate more or diverse tumor types, we
w o u l db ea b l et oi d e n t i f ym o r er e l i a b l eg e n e sa n dp a t h -
ways involved in these common steps.
The large number of expression microarray datasets in
the public domain provides a rich resource for genome-
wide information on cancer and affords an opportunity
to perform meta-analysis with a large number of cases.
Meta-analysis consists of statistical techniques to com-
bine results from several studies in order to increase sta-
tistical power and reproducibility compared with any
single study [6]. Rhodes et al successfully used meta-
analysis to identify a common transcriptional profile
that is universally activated in most cancer types relative
to the normal tissues from which they arose, likely
reflecting essential transcriptional features of neoplastic
transformation [7]. Parmigiani et al also successfully
applied meta-analysis of gene expression to the molecu-
lar classification of lung cancer [8].
Objectives
In this study, we hypothesize that a meta-analysis of
publicly available genomic expression datasets of various
cancer types can identify a common metastatic signature
of metastasis. We tested this hypothesis by implement-
ing and applying a modified permutation meta-analysis
method on multiple microarray datasets and then vali-
dated the signature in independent datasets.
Methods
Eligibility Criteria
We searched the public cancer microarray database,
Oncomine [9], to identify expression microarray datasets
that compared the expression of primary tumors versus
distant metastases of various cancer types. In order to
be included in our study, a dataset was required to (1)
be generated from human tumors, (2) compare primary
tumors versus distant metastatic tumors, (3) have at
least one significant gene with a Q-value < 0.1, and (4)
not include samples that overlapped with those of
another identified dataset. In addition, we eliminated
two datasets with > 50% of the tested genes with Q-
values < 0.1 because of a potential quality issue with the
dataset.
Information sources
Oncomine is the most comprehensive cancer-specific
database currently containing 512 datasets investigating
35 tumor types [9,10]. This database was an excellent
source of datasets for this study because the datasets
contained additional sample information, which was
easily accessible and analyzable. The data obtained is
processed by the Oncomine team prior to export.
Expression values are log-transformed and median-cen-
tered per array. Differential expression is identified by a
permutation test with shrinkage to reduce the noise in
the data, and false discovery rates (Q-value = NP/R,
where P is the p-value, N is the total number of genes
analyzed, and R is the sorted rank of P) are calculated
to correct for multiple testing [11].
Search/Study selection
We performed a simple search for the search term
“met” and obtained 42 studies of which 5 were quickly
eliminated as being non-human studies or for having
evaluated late metastases on primary tumors, instead of
having a sample from the metastasis. We then identified
37 studies [5,12-43] in the Oncomine database that were
analyzed on the basis of primary tumor versus metasta-
sis. Cited literature was reviewed to confirm that the
analysis was as documented in the Oncomine database.
Data collection process/Data items
For each of the identified studies, data for all genes with
a Q-value less than 0.1 were extracted from the database
as a .csv file. Since Oncomine does not allow the export
of the raw data, the extracted data included gene sym-
bol, reporter ID, mean expression levels in the primary
and metastatic tumors, p-value, and calculated Q-value
of each feature or gene.
Summary measures
Since the raw data were not available for some of these
studies, we decided to use a counting method that could
make us of the differential expression information from
the Oncomine database for the meta-analysis. We modi-
fied a meta-analysis method that was originally reported
by Rhodes et al. [7] and implemented it in the R
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essentially counts the number of datasets in which each
gene is significantly differentially expressed and per-
forms permutations in order to determine the signifi-
cance of being differentially expressed in each number
of studies. Our improvement on the method involved
the definition of the False Discovery Proportion (FDP)
which was a cumulative measure of the false discovery
rate that smoothed the curve as the number of repeated
genes decreased and was more sensitive in identifying
genes of interest than the original method based on
comparative analysis of the two methods. This measure,
FDPk, is the number of genes present in k or more stu-
dies as found by random permutation divided by the
observed number of genes present in k or more studies.
The code for this implementation is available upon
request. The algorithm included the following steps:
▪ As e to fS differential expression datasets was
selected.
▪ For each dataset, two signatures were created. One
consisted of unique genes that were under-expressed
metastases versus primary tumors in the dataset
with a Q-value < 0.1, and the other consisted of
those unique genes over-expressed with a Q-value <
0.1.
▪ Each of the following steps of the algorithm was
performed separately for the over- and under-
expressed genes.
▪ For each gene, the number of signatures (from 0
to S)i nw h i c hi tw a sp r e s e n tw a sc o u n t e d( i . e .t h e
number of studies in which it was significantly dif-
ferentially expressed between primary and
metastases.)
▪ The total number of genes, Oj, present in exactly j
signatures was tallied (O1,O 2, ..., OS). (For a
hypothetical example, see Figure 1.)
▪ Random permutations were performed in which
the same set of Q-values was randomly assigned to
the unique genes within each study, so that the set
of genes in each signature changed at random, but
the number of significant genes in each individual
study and the genes at risk for inclusion remained
the same.
▪ Each permutation generated a tally of the number
of genes, Ej, found to be present in j random signa-
tures by chance alone (E1,E 2,...,ES)
▪ The procedure was repeated 1000 times resulting
in a matrix Eij where i was the permutation and j
was the number of signatures
▪ A False Discovery Proportion was calculated for
each number of studies k where
FDPk =
S 
j=k

1000 
1
Ei,j

1000

S 
j=k
Oj
▪ An FDP < 0.1 was considered significant. The
genes that met the FDP cutoff were selected as the
common metastatic signature of metastasis.
Other analyses
Pathway analysis
Using the commercial pathways knowledge database
Ingenuity Pathways Analysis (IPA), we identified canoni-
cal pathways that were enriched or over-represented in
the common metastatic signature [45]. Canonical path-
way analysis identified the pathways from the IPA
library of canonical pathways that were most significant
to the metastatic signature. Genes in the signature of
metastasis that were associated with a canonical pathway
in Ingenuity’s Knowledge Base were considered for the
analysis. The significance of the association between the
signature and the canonical pathway was measured in 3
ways: 1) A ratio of the number of genes from the
Figure 1 Example of the identification of the Oi in the meta-
analysis method. Each of the circles represents a hypothetical
dataset (S1 to S4). The numerals are the number of genes
differentially expressed in the datasets represented by that area of
overlap of the circles. The value Oi is defined as the number of
genes differentially expressed in exactly i number of datasets. In the
example, O1 is 85 since that is the number of genes differentially
expressed in 1 study, whereas O4 is 1 since only one gene is
present in the area overlapping all 4 studies.
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number of genes that map to the canonical pathway was
calculated; 2) A right-sided Fisher’s exact test was used
to calculate a p-value determining the probability that
the association between the genes in the dataset and the
canonical pathway is explained by chance alone; 3) Ben-
jamini-Hochberg (B-H) method of multiple testing cor-
rection was performed [46]. We then performed
PubMed literature review to test if the pathways that
were significant with a B-H p-value less than 0.05 had
been previously implicated in metastasis and mapped
these pathways to the known metastatic cascade.
Validation
In order to perform bioinformatic validation of the gene
signature, we downloaded the raw data for the ten stu-
dies identified in the Oncomine database that were
reserved for validation as described above. After import-
ing and processing the raw data in BRB-ArrayTools
v3.7.0 [47], we used the Gene Set Expression Compari-
son tool to compute the LS statistic p-value for our
metastatic signature for each study. The LS statistic
tests whether the average degree of differential expres-
sion is greater than expected from a random sample of
genes. For a set of N genes, the LS statistic is defined as
LS =
N 
i=1
(−log(pi))
N
where the pi are the p-values of the appropriate single
gene univariate test. The statistical significance of a gene
set, i.e. the LS statistic p-value, is then determined by
comparison of the LS statistic to the empirical distribu-
tion of LS in random samples of N genes. If significant,
it provides evidence that the genes within our metastatic
signature are differentially expressed between primary
tumors and metastases within the validation dataset
more often than would be expected by chance alone
[48]. This was performed separately for our up-regulated
and down-regulated genes. For instance, for the down-
regulated genes, the metastatic signature down-regulated
genes were analyzed in a filtered list of all the down-
regulated genes in the validation dataset.
Results
Study Selection
The datasets were obtained from Oncomine, and eligible
datasets were selected as outlined in Figure 2. Two were
eliminated for potentially having overlapping data with a
previously identified dataset [5,35]. Thirty of the remaining
datasets (81% of the initial 37 datasets) were found to have
significantly altered genes with a Q-value < 0.1. Twenty
eight of these (75.6% of the initial 37 datasets) met our
eligibility criteria and were included in this analysis. The
eligible datasets analyzed the genomic expression of pri-
mary tumors versus metastases in multiple different tumor
types including melanoma and sarcomas, in addition to
various adenocarcinomas. We then set aside ten datasets
that had downloadable raw data in the Gene Expression
Omnibus (GEO) [49] or the Stanford Microarray Database
(SMD) [50] for possible use as validation sets. Upon
further review, four validation datasets were eliminated for
reasons outlined in Figure 3. The eligible datasets involved
various tumor types, including colon cancer, prostate can-
cer, melanoma, sarcoma, and ovarian cancer.
Study characteristics
The datasets that were selected for analysis along with
their respective number of unique genes tested and the
number of genes with a Q-value less than 0.1 are listed
in Table 1. The references and accession numbers are
also provided in the table.
Synthesis of results
To identify a common metastatic signature in solid
tumors, we implemented a modified permutation
Figure 2 Flow diagram of the selection of datasets included in
the meta-analysis. After initial screening and identification of
potential datasets in the Oncomine database, the process of
elimination of ineligible studies is outlined. n: number of datasets in
a specific category; numbers in brackets: reference for the dataset.
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order to perform a meta-analysis of 18 publicly available
expression microarray datasets extracted from the
Oncomine database (Table 1). Based on the meta-analy-
sis, we discovered that down-regulated genes that were
present in four or more studies and up-regulated genes
in five or more studies were more prevalent than would
be expected by chance alone with a False Discovery Pro-
portion (FDP) of less than 0.1 (See Figure 4). Interest-
ingly, we identified 78 (44 + 27 + 6 + 1) down-regulated
genes and only 1 up-regulated gene in metastases com-
pared with primary tumors. These differentially
expressed genes constituted a common signature of
metastasis and are listed in Table 2. As expected, those
datasets that had more differentially expressed genes
contributed more to the metastatic signature than those
with fewer genes (See Figure 5). However, all but three
of the datasets contributed at least one gene to the com-
mon metastatic signature. The specific datasets in which
a specific signature gene was significant with a FDP <
0.1 are listed in the Table 3.
This study expanded upon the previous study by
Ramaswamy et al by including multiple cancer types, as
opposed to only adenocarcinomas [5]. Our method was
able to capture 5 of the 17 genes in the Ramaswamy
metastatic signature. These genes were found to be
down-regulated in both signatures: ACTG2, MYLK,
MYH11, CNN1, and NR4A2. The only up-regulated
gene, EZH2, identified in our study was not part of the
Ramaswamy signature though the gene was up-regulated
with respect to metastasis in the Ramaswamy Multi-can-
cer dataset comparing primary tumors versus metastases
in Oncomine with a Q-value of 0.05. This suggests that
our meta-analysis procedure may identify additional
metastatic genes that have not been reported before, but
are supported by multiple expression studies.
Other analyses
Pathway analysis of genes involved in the common
metastatic signature
To validate whether this signature contains metastasis
information, we identified the pathways that are signifi-
cantly enriched in the signature. Ingenuity Pathway
Analysis revealed that the down-regulated genes in the
metastatic signature were enriched in many pathways
previously implicated in metastasis, such as integrin sig-
naling, calcium signaling, and VEGF signaling. The sig-
nificant pathways are shown in Table 4. In order to
determine whether these pathways were potentially spe-
cific to the EMT, and therefore epithelial tumors, or
whether they could represent common steps that could
be shared with non-epithelial tumors, we mapped these
pathways to steps in the metastatic cascade in which
they had been previously implicated in the literature.
Interestingly, each one of the steps in the metastatic cas-
cade has been reported to be associated with one or
more of our significant pathways (See Figure 6), suggest-
ing the metastatic signature potentially contains infor-
mation throughout the whole metastatic cascade.
Validation of the common metastatic signature
To validate that the common metastatic signature could
be applied to other metastatic datasets, we performed
Gene Set Expression Comparison analysis on six inde-
pendent gene expression datasets identified through
Oncomine that were not used in the meta-analysis. We
found that the common metastatic signature was signifi-
cantly enriched in four out of six of the publicly avail-
able datasets (See Table 5). The signature was enriched,
with an LS statistic p-value < 0.05, in prostate cancer,
gastric cancer, colon cancer, and melanoma datasets
[15,21,33,39]. This supports our hypothesis that this
common metastatic signature is enriched in multiple
tumor types. There were two datasets, an ovarian and
sarcoma dataset, tested in which the common metastatic
signature was not significantly enriched [25,37]. This
may be due to the fact that these tumor types are not
well represented in our discovery set and the number of
significant genes of these tumor types in the discovery
sets is not high. We did attempt to vary the Q-value
cutoff from 0.01 to 0.2 in order to vary the number of
significant genes represented from these datasets, but
this did not improve the validation results. Further stu-
dies may need to be performed to test this possibility
Figure 3 Flow diagram of the selection of studies included for
validation. The process of selection of possible validation datasets
is outlined. n: number of datasets in a specific category; numbers in
brackets: reference for the dataset described; GEO: Gene Expression
Omnibus [49]; SMD: Stanford Microarray Database [50].
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able. However, the common metastatic signature was
enriched in other tumor types that were underrepre-
sented in our meta-analysis, such as gastric cancer that
was not present in the discovery set, suggesting that the
validation results are not simply due to the presence or
absence of the same tumor types in the discovery and
validation sets.
Discussion
Summary of the evidence
We have used a meta-analysis method to identify genes
are shared and important in metastasis. The fact that
these genes are involved in pathways that have been
previously implicated in metastasis supports their invol-
vement in the metastatic process. These genes may be
useful as potential therapeutic targets or predicting clini-
cal outcome. Since these genes and pathways are com-
mon to multiple tumor types as shown by the fact that
they are enriched in various tumors, these may be tar-
gets that can be exploited in many different tumors.
Drug discovery could be performed by finding inhibitors
of identified pathways, such as FAK inhibitors.
One promising in silico approach of drug discovery is
the use of the Connectivity Map to find drugs that can
reverse a gene signature, such as the common metastatic
Table 1 Expression microarray studies used in the meta-analysis
Study [Reference] Platform Unique Genes
Tested
Genes Sig Up
(% of tested)
Genes Sig
Down
(% of tested)
Primary
tumors
Distant
Mets
GEO
Accession
1 Bittner Breast [14] HG U133 Plus 2.0 19079 33
(0.2%)
0
(0%)
327 9 GSE2109
2 Bittner Colon [14] HG U133 Plus 2.0 19079 656
(3.4%)
3938
(20.6%)
330 43 GSE2109
3 Bittner Lung [14] HG U133 Plus 2.0 19079 127
(0.6%)
15
(0.1%)
101 8 GSE2109
4 Bittner Ovarian [14] HG U133 Plus 2.0 19079 494
(2.6%)
131
(0.7%)
166 75 GSE2109
5 Bittner Sarcoma [14] HG U133 Plus 2.0 19079 4
(0%)
1
(0%)
42 10 GSE2109
6 Garber Lung [16] Institutional cDNA
microarray
10723 9
(0.1%)
57
(0.5%)
61 6 GSE3398
7 Graudens Colon [17] Institutional cDNA
microarray
6242 145
(2.3%)
80
(1.3%)
18 30 GSE3964
8 Haqq Melanoma [18] Research Genetics cDNA
microarray
7344 420
(5.7%)
639
(8.7%)
6 19 N/A
9 Holzbeierlein Prostate
[19]
HG U95A-Av2 7820 11
(0.1%)
295
(3.8%)
40 9 N/A
10 Jain Endocrine [20] HG U95A-Av2 7820 14
(0.2%)
229
(2.9%)
8 17 N/A
11 Lapointe Prostate [22] Institutional cDNA
microarray
10021 1081
(10.8%)
1219
(12.2%)
62 9 GSE3933
12 LaTulippe Prostate
[23]
HG U95A-Av2 7820 265
(3.4%)
245
(3.1%)
23 9 N/A
13 Magee Prostate [26] HG FL 4564 35
(0.8%)
18
(0.4%)
8 3 N/A
14 O’Donnell Oral [30] HG U133A 12427 1
(0%)
28
(0.2%)
22 5 GSE2280
15 Radvanyi Breast [31] Custom cDNA microarray 16133 548
(3.3%)
85
(0.5%)
47 7 GSE1477
16 Ramaswamy
Multicancer [32]
HG FL, Hu35KsubA 9064 556
(3.4%)
301
(3.3%)
10 4 N/A
17 Segal Sarcoma [34] HG U95A-Av2 7820 168
(2.1%)
164
(2.1%)
29 4 N/A
18 Vanaja Prostate [38] HG U133A,
HG U133B
17358 4
(0%)
208
(1.2%)
27 5 N/A
The 18 datasets used in the meta-analysis are described with regard to the platform used in the original experiment, the number of unique genes represented in
the platform, the number of genes significantly (sig) dysregulated in metastases compared with primaries with a Q-value < 0.1, the number of samples that are
primary tumors or distant metastases (mets), and the Gene Expression Omnibus (GEO) Accession number. HG U133 Plus 2: Affymetrix Human Genome U133 Plus
2.0 Array; HG U95A0Av2: Affymetrix Human Genome U95A-Av2 Array; HG FL: Affymetrix HumanGeneFL Array; HG U133A: Affymetrix Human Genome U133A
Array: HG U133B: Affymetrix Human Genome U133B Array; N/A: Not applicable.
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phenotype [51,52]. On preliminary analysis of the meta-
static signature by the Connectivity Map, the top molecule
that could reverse the common metastatic signature by
the permutation analysis was camptothecin. Camptothecin
is a topoisomerase I inhibitor that has been shown to
induce apoptosis in tumor cells. Irinotecan and topotecan,
which are analogs of camptothecin, are currently being
used to treat several cancers including colon cancer, ovar-
ian cancer, and gliomas [53]. Interestingly, when ranking
the drugs by Anatomical Therapeutic Chemical (ATC)
codes, the top three ranking codes were all groups of anti-
psychotics, which may be related to the ability of some of
these compounds to induce autophagy in experimental
models [54]. The molecules in these groups were signifi-
cantly associated with reversal of the metastatic signature
with good specificity for the signature. This may represent
known and readily available drugs that could have a new
application immediately without the need of developing a
new compound, which would take many years of testing.
The result of this in silico analysis can only be confirmed
with more analyses and experiments; however, this shows
the promise of applying this signature to the prediction
and therapy of metastatic cancers for improving the out-
comes of patients.
Though all of the genes in our signature were differ-
entially expressed in more studies than would be
expected by chance alone, it is important to note that
Figure 4 Average observed by permutation versus observed dysregulated genes found by the meta-analysis method. The number of
genes expected to be repeated as calculated by our permutation method and the number of repeated genes observed in our datasets is
plotted against the number of studies (x) in which they are repeated (4a shows the results for the up-regulated genes; 4c is the results for the
down-regulated genes). The actual numbers are presented in the tables below the corresponding chart (4b corresponds with up-regulated, and
4d with down). The observed repeated genes are greater than the expected number when significant in 2 datasets. This was considered
significant when the FDP < 0.1.
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were present in more than 8 of our 18 datasets. This
could be caused by many factors, such as heterogeneity
of metastatic tumors, dataset quality, and the use of dif-
ferent platforms without uniform representation of
genes of interest. This may explain the difficulty many
individuals have found in identifying overlapping genes
in multiple datasets examining metastasis [55]. In addi-
tion, more overlapping genes may not have been
identified because of a potential lack of power caused by
using a stringent Q-value of 0.1. However, this high-
lights the usefulness of the meta-analysis approach in
identifying significant metastatic genes that repeat more
than expected by chance that may not be identified
when initially comparing datasets.
In our analysis, we have also noted that the number of
down-regulated genes is much greater than the number of
up-regulated genes. This intriguing observation suggests
that overcoming metastatic suppression may be a critical
or common step in tumor progression. Alternatively, the
genes involved in metastasis suppression may be more
similar and shared among the solid tumors than those
involved in metastasis activation processes. It has been
previously shown that down-regulation of certain genes,
such as KISS1, RhoGDI2, and nm23-H1, is important in
metastasis [56]. At least one of our identified down-regu-
lated genes, CDGF, is a recognized metastasis suppressor
gene [4]. In addition, two of the most highly dysregulated
pathways, the actin cytoskeleton signaling pathway and
the regulation of actin motility by Rho, have been asso-
ciated with multiple metastasis suppressor genes [56]. We
expect that further functional studies of the down-regu-
lated genes in our common signature will reveal novel
metastasis suppressor genes.
The future applications of this meta-analysis method
are numerous, as the number of gene expression
Table 2 The Common Metastatic Signature
Number of
studies repeated
Up-regulated
in metastasis
Down-regulated
in metastasis
4 studies Not significant ACTG2 GJA1 NBL1 RARRES1
CASP7 GNG12 PAGE4 SELE
CSRP1 GSN PAM SLC12A4
CYR61 IER2 PCP4 SMTN
DPT ISL1 PDE4D SORBS1
DSTN JMJD3 PIGB SYNPO2
FILIP1L JUNB PKIG TCF21
FLNC KRT15 PLA2G2A TMEM49
FOSB LUM PLEKHC1 TPM1
FUCA1 MAPK1 PPP1R12A TSC22D1
GADD45B MFAP4 RAP1A VCL
5 studies EZH2 ACTA2 DKFZP564O0823 LMOD1 RBPMS
BMPR1A DMN MCL1 SPARCL1
CAMK2G FBLN1 MGP SPG20
CCND2 FHL1 NR4A1 TACC1
CNN1 FXYD3 NR4A3 TAGLN
CTGF HBEGF PPP1R12B ZFP36
DIO2 KCNMA1 PYROXD1
6 studies None BTG2 KCNMB1 MYLK
JUND MYH11 SOD3
8 studies None TPM2
The gene symbols of the genes in the metastatic signature are given with along with the number of studies in which it was significant.
Figure 5 Number of genes in the common metastatic
signature significant (Q-value < 0.1) in each dataset. N: Number
of unique genes differentially expressed with a Q-value < 0.1.
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Genes differentially
expressed in metastasis
1234567891 01 11 21 31 41 51 61 71 8 N u m studies
Up - regulated genes
EZH2 X X X X X 5
Down - regulated genes
ACTG2 X X X X 4
FUCA1 X X X X 4
JUNB X X X X 4
PDE4D X X X X 4
RAP1A X X X X 4
SYNPO2 X X X X 4
CASP7 X X X X 4
GADD45B X X X X 4
KRT15 X X X X 4
PIGB X X X X 4
RARRES1 X X X X 4
TCF21 X X X X 4
CSRP1 X X X X 4
GJA1 X X X X 4
LUM X X X X 4
PKIG X X X X 4
SELE X X X X 4
TMEM49 X X X X 4
CYR61 X X X X 4
GNG12 X X X X 4
MAPK1 X X X X 4
PLA2G2A X X X X 4
SLC12A4 X X X X 4
TPM1 X X X X 4
DPT X X X X 4
GSN X X X X 4
MFAP4 X X X X 4
PLEKHC1 X X X X 4
SMTN X X X X 4
TSC22D1 X X X X 4
DSTN X X X X 4
IER2 X X X X 4
NBL1 X X X X 4
PPP1R12A X X X X 4
SORBS1 X X X X 4
VCL X X X X 4
FILIP1L X X X X 4
ISL1 X X X X 4
PAGE4 X X X X 4
FLNC X X X X 4
JMJD3 X X X X 4
PAM X X X X 4
FOSB X X X X 4
PCP4 XX X X 4
ACTA2 X X X X X 5
CNN1 X X X X X 5
D M N X XXXX 5
HBEGF X X X X X 5
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Page 9 of 14datasets increases. For instance, in the field of metasta-
sis, this method could be used to compare patients with
primary tumors that are metastatic versus non-meta-
static. This may add to the information we have learned
f r o mt h ep r e s e n ts t u d y .A tt h et i m ew h e ns t u d yw a s
started, the Oncomine database did not provide enough
detailed clinical information to perform this analysis.
However, this may be feasible in the future.
Limitations
As with any meta-analysis, the results are dependent
upon the reliability of the original data [6]. However, it
was difficult to test the validity of the original experi-
ments without raw data. This quality issue was partially
overcome by the use of our criteria to select the studies
for the meta-analysis and by the use of the meta-analysis
approach itself. Our selection criteria excluded the out-
liers in our analysis, such as datasets without any
significant genes with a Q-value less than 0.1 and those
with greater than 50% of the tested genes being signifi-
cant which we hypothesize might be due to systemic
bias rather than true differences. Additionally, the pro-
cess of combining different studies into one analysis
should theoretically minimize the effect of some of the
possible confounders or quality issues that may be pre-
sent in certain studies. Since any gene in our signature
had to be repeated in multiple studies (i.e. in four or
more for the down-regulated genes), no one study alone
could completely invalidate our gene list. Clinical meta-
analyses often test for heterogeneity of studies, but this
approach has not been extended to the meta-analysis of
genomic studies.
There are several areas for improvement that could be
addressed in future studies. One limitation we had to
overcome was the fact that it was not possible to down-
load the complete datasets from the Oncomine database,
Table 3 Datasets in which genes in common metastatic signature of metastasis are significant with a Q ?<? 0.1
(Continued)
MGP X X X X X 5
PYRO1D1 X X X X X 5
TACC1 X X X X X 5
BMPR1A X X X X X 5
CTGF X X X X X 5
FBLN1 X X X X X 5
KCNMA1 X X X X X 5
NR4A1 X X X X X 5
RBPMS X X X X X 5
TAGLN X X X X X 5
CAMK2G X X X X X 5
DIO2 X X X X X 5
FHL1 X X X X X 5
LMOD1 X X X X X 5
NR4A3 X X X X X 5
SPARCL1 X X X X X 5
ZFP36 X X X X X 5
CCND2 X X X X X 5
DKFZP564O0823 X X X X X 5
FXYD3 X X X X X 5
MCL1 X X X X X 5
PPP1R12B X X X X X 5
SPG20 X X X X X 5
BTG2 X X X X X X 6
JUND X X X X X X 6
KCNMB1 X X X X X X 6
MYH11 X X X X X X 6
MYLK X X X X X X 6
SOD3 X X X X X X 6
TPM2 X X X X X X X X 8
The studies in which each gene is differentially expressed are given as an × under the study number, as given in Table 1. “Num studies” refers to the total
number of studies in which the gene is significantly differentially expressed with a Q-value < 0.1.
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Page 10 of 14and we were unable to find raw data for most of older
studies included in our signature. Therefore, we were
unable to compare the complete lists of genes tested
and potentially capture genes that were only represented
in a small number of platforms by performing more
advanced meta-analysis methods, specifically one that
could provide weighting based on the number of genes
and samples in the initial experiment, such as the
weighted z-method [57]. Limiting the study to only
those datasets with available raw data would have sub-
stantially reduced the number of studies and possibly
the power to detect genes of interest. The counting
method we performed in this study was only dependent
on information of the significant gene lists which
allowed the use of the maximum number of array stu-
dies. In the future, as more datasets are readily available
for download, this problem may be overcome. This cur-
rent limitation, however, does not affect the conclusion
that those genes identified in this study are likely to be
of importance. We conclude that this method has good
specificity but may have less sensitivity (a higher false
negative rate) than other meta-analysis approaches.
Inconsistent gene ontology also complicated the analy-
sis in this study. Since the Oncomine database provides
only the Gene Symbol and only one other gene identi-
fier that could not be matched for every dataset, the
only common identifier between our validation datasets
and the datasets used in the meta-analysis was the gene
symbol. However, a gene symbol may map to multiple
probes, so we could be counting results of different
probes in each dataset. We did ensure that we counted
each unique gene symbol only once in each direction by
manually removing duplicates in our extracted data
prior to running the meta-analysis. In addition, the use
of gene symbols forced us to eliminate from our com-
parison many ESTs that could have been found in mul-
tiple studies. This highlights the need for a common
identifier standardized across platforms, such as Entrez
gene IDs, which will help to identify more common
metastatic genes.
Lastly, the majority of studies used in the meta-analy-
sis were from epithelial tumors reflecting their predomi-
nance in the population and, hence, the microarray
studies. Attempts to remove these epithelial cancer data-
sets, such as prostate cancers, resulted in lack of power
to identify significant metastatic genes. This could be
due to a more dramatic biological effect of metastasis in
these epithelial tumors, or the power of the studies
themselves, such as a larger sample size and less tissue
heterogeneity, etc. This is a limitation of our study due
to the availability of eligible datasets in the Oncomine
database. With the accumulation of more datasets for
non-epithelial, non-adenocarcinoma tumors, future stu-
dies may be able to incorporate them and identify a
more refined common signature of metastasis that is
applicable to even more tumor types.
Table 4 Ingenuity canonical pathways significantly (B-H p-value < 0.05) represented by the genes down-regulated in
the common metastatic signature
Ingenuity Canonical Pathways Fisher Exact
p-value
B-H
p-value
Ratio
Actin Cytoskeleton Signaling 7.94E-08 1.51E-05 4.26E-02
Regulation of Actin-based Motility by Rho 3.89E-06 2.14E-04 6.52E-02
Integrin Signaling 4.57E-06 2.14E-04 3.96E-02
Calcium Signaling 2.24E-05 7.08E-04 3.41E-02
Protein Kinase A Signaling 1.12E-04 3.02E-03 2.51E-02
RhoA Signaling 1.86E-04 4.27E-03 4.55E-02
NRF2-mediated Oxidative Stress Response 2.00E-04 4.27E-03 3.28E-02
ILK Signaling 2.51E-04 4.68E-03 3.23E-02
Thrombin Signaling 3.39E-04 5.75E-03 2.94E-02
Chemokine Signaling 4.17E-04 6.61E-03 5.33E-02
VEGF Signaling 8.32E-04 1.07E-02 4.12E-02
FAK Signaling 8.71E-04 1.07E-02 4.00E-02
Phospholipase C Signaling 9.12E-04 1.07E-02 2.34E-02
cAMP-mediated Signaling 1.02E-03 1.15E-02 3.11E-02
Tight Junction Signaling 1.15E-03 1.20E-02 2.99E-02
Relaxin Signaling 3.47E-03 2.95E-02 2.68E-02
CDK5 Signaling 9.12E-03 6.17E-02 3.19E-02
IL-8 Signaling 9.33E-03 6.17E-02 2.15E-02
B-H: Benjamini-Hochberg method for correcting for the multiple testing problem; Ratio: The number of genes from the metastatic signature that map to the
pathway divided by the total number of genes that map to the canonical pathway.
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Page 11 of 14Figure 6 Mapping of common pathways represented by gene list to metastatic cascade. Ingenuity pathways significantly enriched by the
common metastatic signature with a p-value < 0.01 were mapped to the metastatic cascade after a literature review. The figure is based on the
metastatic cascade as published by Isaiah Fidler in 2003 [3].
Table 5 Enrichment of the common metastatic-signature (CMS)
Study
[Reference]
Platform Unique Genes
Tested
Primary
Tumors
Distant
Mets
Unique CMS Genes
in dataset
Significant
CMS Genes
LS
Statistic
p-value
GEO Acc # or
SMD Pub #
Varambally
Prostate [39]
HG U133 Plus 2.0 19079 7 6 65 57 <
0.00001
GSE3325
Chen Gastric
[15]
Undefined cDNA
microarray
10568 89 14 61 26 <
0.00001
SMD Pub # 232
Ki Colon [21] CMRC-GT 9078 52 28 55 25 0.00011 GSE6988
Riker Melanoma
[33]
HG U133 Plus 2.0 19079 16 40 71 17 0.011 GSE7553
Linn Sarcoma
[25]
Undefined cDNA
microarray
14437 47 10 61 5 0.50 SMD Pub # 287
Tothill Ovarian
[37]
HG U133 Plus 2.0 19079 189 54 65 7 0.93 GSE9899
The 6 validation datasets with regard to the platform used in the original experiment, the number of unique genes represented in the platform, the number of
samples that are primary tumors or distant metastases (mets), the number of genes in the common metastatic signature (CMS) represented in the platform, the
number of CMS genes that were significant with a Q-value < 0.1, the LS statistic p-value, and the Gene Expression Omnibus Accession number (GEO Acc #) or
SMD Publication number (SMD Pub #). HG U133 Plus 2: Affymetrix Human Genome U133 Plus 2.0 Array; CMRC-GT: Cancer Metastasis Research Center-Genomic
Tree array, Yonsei Cancer Center, Seoul, Korea.
Daves et al. BMC Medical Genomics 2011, 4:56
http://www.biomedcentral.com/1755-8794/4/56
Page 12 of 14Conclusions
We have developed a modified meta-analysis counting
method and applied it to the comparison of primary
tumors versus metastases in various tumor types. We
identified a list of 78 down-regulated genes and 1 up-
regulated gene in metastases compared to primary
tumors with a False Discovery Proportion of less than
0.1. Many of these genes are involved in pathways asso-
ciated with metastasis. After comparing the list of genes
generated by our analysis with six independent datasets
testing primaries versus metastases, we found that four
of the datasets demonstrated that these genes were dys-
regulated than would be expected by chance alone (i.e.
LS-statistic p-value < 0.05). We believe that the identifi-
cation of this common metastatic signature could facili-
tate further research in metastasis, such as outcome
prediction, drug discovery, and other functional studies.
We have followed the relevant components of the
PRISMA 2009 guidelines in the preparation of this
manuscript [58].
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